Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solnatide - APEPTICO

Next Previous
Search
Drug Profile

Solnatide - APEPTICO

Alternative Names: AP-301

Latest Information Update: 01 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator APEPTICO Forschung und Entwicklung
  • Class Peptides
  • Mechanism of Action Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury; Acute lung injury; Pulmonary oedema; Pseudohypoaldosteronism
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; Pulmonary oedema; Reperfusion injury
  • No development reported Pseudohypoaldosteronism

Most Recent Events

  • 01 Dec 2022 No development reported - Phase-II for Pulmonary oedema in Austria (Inhalation) (Apeptico website, November 2022)
  • 08 Sep 2021 APEPTICO Forschung und Entwicklung terminates its phase II clinical trial in Pulmonary oedema (in SARS-Cov-2 positive patients with ARDS) in Austria (Inhalation, Powder) (EudraCT2020-001244-26)
  • 28 Apr 2020 Italian Medicines Agency and the Ethics Committee of the National Institute for Infectious Diseases (Lazzaro Spallanzani-Rome) approves solnatide for compassionate use for COVID-19 infections in Italy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top